CTX-10726
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Cancer (GC)
Conditions
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Trial Timeline
Apr 1, 2026 → Nov 1, 2028
NCT ID
NCT07419841About CTX-10726
CTX-10726 is a phase 1 stage product being developed by Compass Therapeutics for Gastroesophageal Cancer (GC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07419841. Target conditions include Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07419841 | Phase 1 | Recruiting |
Competing Products
20 competing products in Gastroesophageal Cancer (GC)